| pubmed-article:3335895 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:3335895 | lifeskim:mentions | umls-concept:C0029925 | lld:lifeskim |
| pubmed-article:3335895 | lifeskim:mentions | umls-concept:C0282460 | lld:lifeskim |
| pubmed-article:3335895 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:3335895 | lifeskim:mentions | umls-concept:C0057856 | lld:lifeskim |
| pubmed-article:3335895 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:3335895 | pubmed:dateCreated | 1988-2-23 | lld:pubmed |
| pubmed-article:3335895 | pubmed:abstractText | Iproplatin (cis-dichloro-trans dihydroxy-bis-isopropyl-amine platinum [IV]; CHIP) was administered intravenously (IV) at monthly intervals at doses of 300 mg/m2 and 240 mg/m2 to ten previously untreated and 97 previously treated patients with advanced ovarian carcinoma. The overall response rate was 78% among patients with no prior chemotherapy, 42% among patients with prior chemotherapy not including cisplatin, and 22% among patients with prior chemotherapy including cisplatin. Overall response rates to iproplatin were 6.4% and 54% in patients with/without clinical evidence of tumor resistance to cisplatin. Thrombocytopenia was the dose-limiting toxicity, median time to nadir and to recovery being 2 and 4 weeks, respectively. Patients who had received prior chemotherapy regimens for greater than 1 year showed a 10% greater reduction in platelet count (mean platelet nadir +/- SD, 57.5 +/- 49.96 X 10(3)/microL) and a higher incidence of grade 3 to 4 thrombocytopenia after the first cycle than patients who had received prior chemotherapy regimens for less than 1 year (94.7 +/- 65.99 X 10(3)/microL) Moderate to severe vomiting and diarrhea occurred in 84% and 16% of patients pretreated with chemotherapy. Neuropathy (6%) was reported only in patients with prior cisplatin treatment. Mild and reversible renal toxicity was observed in 6% of cases. Iproplatin is an active drug in ovarian cancer; the results achieved in patients previously treated with cisplatin strongly suggest that the two drugs are cross-resistant. | lld:pubmed |
| pubmed-article:3335895 | pubmed:language | eng | lld:pubmed |
| pubmed-article:3335895 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3335895 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:3335895 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3335895 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3335895 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3335895 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3335895 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:3335895 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:3335895 | pubmed:issn | 0732-183X | lld:pubmed |
| pubmed-article:3335895 | pubmed:author | pubmed-author:SmithDD | lld:pubmed |
| pubmed-article:3335895 | pubmed:author | pubmed-author:CavalliFF | lld:pubmed |
| pubmed-article:3335895 | pubmed:author | pubmed-author:KayeSS | lld:pubmed |
| pubmed-article:3335895 | pubmed:author | pubmed-author:RenardJJ | lld:pubmed |
| pubmed-article:3335895 | pubmed:author | pubmed-author:SessaCC | lld:pubmed |
| pubmed-article:3335895 | pubmed:author | pubmed-author:ten Bokkel... | lld:pubmed |
| pubmed-article:3335895 | pubmed:author | pubmed-author:VermorkenJJ | lld:pubmed |
| pubmed-article:3335895 | pubmed:author | pubmed-author:PinedoHH | lld:pubmed |
| pubmed-article:3335895 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:3335895 | pubmed:volume | 6 | lld:pubmed |
| pubmed-article:3335895 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:3335895 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:3335895 | pubmed:pagination | 98-105 | lld:pubmed |
| pubmed-article:3335895 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:3335895 | pubmed:meshHeading | pubmed-meshheading:3335895-... | lld:pubmed |
| pubmed-article:3335895 | pubmed:meshHeading | pubmed-meshheading:3335895-... | lld:pubmed |
| pubmed-article:3335895 | pubmed:meshHeading | pubmed-meshheading:3335895-... | lld:pubmed |
| pubmed-article:3335895 | pubmed:meshHeading | pubmed-meshheading:3335895-... | lld:pubmed |
| pubmed-article:3335895 | pubmed:meshHeading | pubmed-meshheading:3335895-... | lld:pubmed |
| pubmed-article:3335895 | pubmed:meshHeading | pubmed-meshheading:3335895-... | lld:pubmed |
| pubmed-article:3335895 | pubmed:meshHeading | pubmed-meshheading:3335895-... | lld:pubmed |
| pubmed-article:3335895 | pubmed:meshHeading | pubmed-meshheading:3335895-... | lld:pubmed |
| pubmed-article:3335895 | pubmed:meshHeading | pubmed-meshheading:3335895-... | lld:pubmed |
| pubmed-article:3335895 | pubmed:meshHeading | pubmed-meshheading:3335895-... | lld:pubmed |
| pubmed-article:3335895 | pubmed:meshHeading | pubmed-meshheading:3335895-... | lld:pubmed |
| pubmed-article:3335895 | pubmed:meshHeading | pubmed-meshheading:3335895-... | lld:pubmed |
| pubmed-article:3335895 | pubmed:meshHeading | pubmed-meshheading:3335895-... | lld:pubmed |
| pubmed-article:3335895 | pubmed:year | 1988 | lld:pubmed |
| pubmed-article:3335895 | pubmed:articleTitle | Phase II study of iproplatin in advanced ovarian carcinoma. | lld:pubmed |
| pubmed-article:3335895 | pubmed:affiliation | Department of Oncology, Ospedale San Giovanni, Bellinzona, Switzerland. | lld:pubmed |
| pubmed-article:3335895 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3335895 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3335895 | lld:pubmed |
